Brian Elliott

1.3k total citations · 1 hit paper
32 papers, 482 citations indexed

About

Brian Elliott is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Brian Elliott has authored 32 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Brian Elliott's work include CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Brian Elliott is often cited by papers focused on CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Brian Elliott collaborates with scholars based in United States, United Kingdom and Denmark. Brian Elliott's co-authors include Kim Linton, Dena DeMarco, Roberto S Oliveri, Michael Roost Clausen, Martin Hutchings, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Rogier Mous, Peter Johnson and Anna Sureda and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Brian Elliott

29 papers receiving 474 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers

Countries citing papers authored by Brian Elliott

Since Specialization

Citations

This map shows the geographic impact of Brian Elliott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Elliott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Elliott more than expected).

Fields of papers citing papers by Brian Elliott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Elliott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Elliott. The network helps show where Brian Elliott may publish in the future.

Co-authorship network of co-authors of Brian Elliott

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Elliott. A scholar is included among the top collaborators of Brian Elliott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Elliott. Brian Elliott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis	Advances in Therapy	Andrew Ip, Tongsheng Wang et al.	5
2	P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS	HemaSphere	Allison Rosenthal, Javier Muñoz et al.	0
3	ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2	Clinical Lymphoma Myeloma & Leukemia	Laurie H. Sehn, Martine E.D. Chamuleau et al.	1
4	Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas	Clinical Pharmacology & Therapeutics	Tommy Li, Ida H. Hiemstra et al.	25
5	Subcutaneous epcoritamab with rituximab + lenalidomide (R²) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.	Journal of Clinical Oncology	Lorenzo Falchi, Sirpa Leppä et al.	12
6	Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis	Blood	Andrew Ip, Tongsheng Wang et al.	1
7	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study breakdown →	The Lancet	Martin Hutchings, Rogier Mous et al.	212
8	SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY	Hematological Oncology	Martin Hutchings, Rogier Mous et al.	1
9	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.	Journal of Clinical Oncology	Michael Roost Clausen, Pieternella J. Lugtenburg et al.	14
10	Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.	Journal of Clinical Oncology	Martin Hutchings, Pieternella J. Lugtenburg et al.	19
11	Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia	ClinicoEconomics and Outcomes Research	Gabriel Tremblay, Menaka Bhor et al.	8
12	Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia	ClinicoEconomics and Outcomes Research	Gabriel Tremblay, Menaka Bhor et al.	7
13	Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia	Blood	Gabriel Tremblay, Menaka Bhor et al.	1
14	Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study	Blood	Yanni Hao, Alex Z. Fu et al.	2
15	A phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia.	Journal of Clinical Oncology	Richard T. Maziarz, Bart L. Scott et al.	2
16	Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate	Expert Review of Hematology	Brian Elliott, Louis M. Aledort	14
17	Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*	European Journal Of Haematology	Brian Elliott, Keren Osman et al.	28
18	Non‐myeloablative conditioning and allogeneic transplantation for multiple myeloma	American Journal of Hematology	Keren Osman, Brian Elliott et al.	8
19	Viral Vaccines for Cancer Immunotherapy	Hematology/Oncology Clinics of North America	Andrew Eisenberger, Brian Elliott et al.	10
20	External fixation in trauma of the foot and ankle	Clinics in Podiatric Medicine and Surgery	F. J. Seibert, F. Fankhauser et al.	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact